Ai-driven platform for novel fungicide development

Overview

Our AI-driven platform is designed to revolutionize the development of novel fungicides, offering broad applicability across various fungal and yeast pathogens. Initially developed for specialty crops, our proprietary molecules have demonstrated promising efficacy against Candida albicans, a common yeast infection. These molecules are envisioned for low-toxicity, over-the-counter topical treatments, expanding potential market applications.

Technical specifications

• AI-driven development: Utilizes advanced artificial intelligence to design molecules with broad specificity against various fungi and yeast.
• Proven efficacy: Current molecules inhibit growth of Candida albicans, with potential applications in treating vaginal infections.
• Low toxicity: Designed for safe, over-the-counter usage.
• Adaptability: Initially targeted at fungal pathogens in specialty crops, these molecules can be refined for clinical applications.

Technology readiness level

The technology is currently at TRL 4, having shown efficacy in lab tests. Future development aims to refine these molecules specifically for Candida albicans over a 12-18 month period, advancing towards clinical testing and commercialization.